Phase II study of intravenous Doxil® in malignant pleural mesothelioma

Yun Oh, Roman Perez-Soler, Frank V. Fossella, Bonnie S. Glisson, Jonathan Kurie, Garrett L. Walsh, Mylene Truong, Dong M. Shin

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Twenty-four patients with pleural mesothelioma received 50 mg/m2 of Doxil® every four weeks. At follow-up, the disease had stabilized in 43% percent of patients and had progressed in 57%. No objective responses were observed. Estimated median survival of all patients was 37 weeks. Major toxicities were erythrodysesthesia of hands and feet and myelosuppression. No cardiac toxicity was observed. We concluded that Doxil® at this dosage and schedule is inactive against pleural mesothelioma.

Original languageEnglish (US)
Pages (from-to)243-245
Number of pages3
JournalInvestigational New Drugs
Volume18
Issue number3
DOIs
StatePublished - Aug 14 2000
Externally publishedYes

Keywords

  • Doxil®
  • Mesothelioma

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II study of intravenous Doxil® in malignant pleural mesothelioma'. Together they form a unique fingerprint.

  • Cite this

    Oh, Y., Perez-Soler, R., Fossella, F. V., Glisson, B. S., Kurie, J., Walsh, G. L., Truong, M., & Shin, D. M. (2000). Phase II study of intravenous Doxil® in malignant pleural mesothelioma. Investigational New Drugs, 18(3), 243-245. https://doi.org/10.1023/A:1006421706540